Pertuzumab biosimilar (Xuanzhu/SL)

帕妥珠单抗生物药（轩竹/双鹭）

Report date: 2026/05/26 20:00:28

Base Information

Drug NamePertuzumab biosimilar (Xuanzhu/SL)
Drug Alias NameAnti-2C4 monoclonal antibody培妥珠单抗Pertuzumabum珀妥珠单抗帕妥株单抗 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusN/A
Highest Status in ChinaN/A
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co LtdBeijing Sl Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Sl Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG